PMC4678532_01
H&E high power showing high-grade urothelial carcinoma
40425_2015_104_Fig1_HTML.jpg
PMC4678532_01_40425_2015_104_Fig1_HTML.jpg
Fig1
Pathology revealed high-grade urothelial carcinoma invading the renal parenchyma and peripelvic fat without a significant inflammatory component (Fig. 1).
Strongly positive PD-L1 immunostaining (Clarient GE, Inc.) Sections were cut and dewaxed followed by application of the primary PD-L1 antibody (Cell Signaling Co., clone E1L3N, 1:150) and PD-1 antibody (CellMarque Co., clone MRQ-22, 1:300). After washes, DAB was used as the chromogen and slides were counterstained with hematoxylin
40425_2015_104_Fig2_HTML.jpg
PMC4678532_01_40425_2015_104_Fig2_HTML.jpg
Fig2
Subsequently, the patient's primary tumor was tested at Clarient GE, Inc. [Aliso Viejo, CA] for PD-L1 expression and found 2+ staining in 80 % of cells (Fig. 2).
The baseline film in November reveals a necrotic lymph node in the left para-aortic region adjacent to the ureter. The follow-up study in March 2015 shows a complete disappearance of the lesion
40425_2015_104_Fig3_HTML.jpg
PMC4678532_01_40425_2015_104_Fig3_HTML.jpg
Fig3
Within 2 months at the first radiographic evaluation, she had a complete disappearance of all cancer (Fig. 3).